Amyris, Inc., the U.S. industrial bioscience company, and Chevron Products Company, a division of Chevron U.S.A. Inc., announced that Novvi LLC and Chevron have entered into an agreement to jointly develop and bring to market novel renewable base oil technologies. Terms of the transaction were not disclosed.
Amyris, Inc., the industrial bioscience company headquartered in Emeryville, California, has successfully collaborated with its fragrance partner, Firmenich, the world’s largest privately-owned fragrance and flavor company, to support the development and commercialization of Z11.
Amyris, the U.S. industrial bioscience company led by John Melo, closed the second and final tranche of its previously announced financing. The second tranche of $50 million in a private placement was led by a $25 million investment from Koninklijke DSM N.V. (Royal DSM) with the remaining $25 million contributed by Vivo Capital.
Amyris, the U.S. industrial bioscience company, and the Government of Queensland, Australia, announced the next step their plans to develop a leading industrial biotechnology hub in Southeast Asia. Plans call for developing a new production plant with support from local partners to produce Amyris’s sugar cane-based ingredient called farnesene, which is used in products including cosmetic emollients, fragrances, nutraceuticals, polymers, and lubricants.
Amyris, Inc., the U.S. industrial bioscience company, and Koninklijke DSM N.V. (Royal DSM), the Dutch global science-based company active in health, nutrition and materials, have agreed for DSM to make an equity investment in Amyris. At the same time, the companies will enter into a development cooperation focused on products for the global health and nutrition markets (including vitamins and other nutritional ingredients).
The bioeconomy is also new biolubricants, a market segment that is tempting the big oil industry. It is no coincidence that Chevron Products Company, a division of Chevron U.S.A. Inc, has made an equity investment into Novvi LLC (a joint venture of Amyris, Inc., Cosan S.A., and American Refining Group, ARG).
Biossance™, the consumer beauty brand from Amyris, Inc., the US integrated renewable products company, announced its planned launch in Sephora’s retail stores where the brand’s expansive line of high-performance skin care products will be available to consumers. The rollout to initial participating stores will begin in February 2017 and coincide with launching on Sephora online. Additional in-store and online marketing activities with Sephora to highlight the Biossance brand shortly following launch are planned.
Amyris, the U.S. industrial bioscience company, has won a three-year multi-million dollar contract from the U.S. Department of Energy (DOE) to further the manufacturing of cellulose-derived farnesene for biofuels. The company led by John Melo, in cooperation with Renmatix and Total New Energies USA, will work to develop a manufacturing-ready process utilizing wood as the cellulosic feedstock to produce farnesene, a hydrocarbon building block used to manufacture a variety of products ranging from cosmetics to detergents, as well as base oils, lubricants, diesel and jet fuel.
“I expect 30% of jet fuel to be renewable by 2030 and we hope to have at least 1/3 of this market share”. John Melo talks to Il Bioeconomista. In this exclusive interview the President & Ceo of Amyris, the California-based company which has been named the #1 company in the 50 Hottest Companies in the Advanced Bioeconomy (“Hot 50”) contest, talks about his company and the bioeconomy, the role played by the U.S. government and the public opinion. “To me – Melo says – ecology and economy must go together. Producing less CO2 emissions should cost less, not more. When this happens ecology and climate are working in the same direction. What’s good for the planet should be good for business and we are making this a reality”.
Interview by Mario Bonaccorso
Ginkgo Bioworks and Amyris, Inc. announced a new partnership, which will enable the companies to jointly develop products more efficiently and cost effectively, accelerating time to market.
This breakthrough biotech partnership creates clear leadership with a combined offering that has successfully introduced more bio-based products than any other company known in the field. The combined R&D capabilities of Ginkgo and Amyris put both partners at a significant advantage in the industry by leveraging the joint end-to-end technology platform. This partnership is expected to deliver more new cultured ingredients into the global market in the next three years than the total industry has achieved in the last 10 years.